Safety and Efficacy of Steroid Pulse Therapy for Acute Loss of FEV
Journal
Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532
Informations de publication
Date de publication:
Historique:
received:
21
05
2019
accepted:
06
10
2019
pubmed:
14
1
2020
medline:
24
7
2020
entrez:
14
1
2020
Statut:
ppublish
Résumé
The standard treatment of acute cellular rejection after lung transplantation (LTx) is a high-dose steroid pulse therapy. In our center, this therapy is also the standard of care for LTx recipients with acute loss of forced expiratory volume in 1 second (FEV From 2015 to 2018, 33 consecutive patients (17 male patients, mean age ± SD, 50.5 ± 12.5 years) were included. All patients underwent routine examinations to exclude acute cellular rejection and other specific causes. FEV The mean decrease ± SD from baseline in FEV Only a minority of patients after LTx with loss of FEV
Sections du résumé
BACKGROUND
BACKGROUND
The standard treatment of acute cellular rejection after lung transplantation (LTx) is a high-dose steroid pulse therapy. In our center, this therapy is also the standard of care for LTx recipients with acute loss of forced expiratory volume in 1 second (FEV
METHODS
METHODS
From 2015 to 2018, 33 consecutive patients (17 male patients, mean age ± SD, 50.5 ± 12.5 years) were included. All patients underwent routine examinations to exclude acute cellular rejection and other specific causes. FEV
RESULTS
RESULTS
The mean decrease ± SD from baseline in FEV
CONCLUSIONS
CONCLUSIONS
Only a minority of patients after LTx with loss of FEV
Identifiants
pubmed: 31926742
pii: S0041-1345(19)30858-9
doi: 10.1016/j.transproceed.2019.10.013
pii:
doi:
Substances chimiques
Glucocorticoids
0
Prednisone
VB0R961HZT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
309-314Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.